Does the Pharvaris (PHVS) Form 3 indicate any recent share purchases or sales?

The Form 3 functions as an initial ownership statement and lists holdings rather than trades. The transactions are categorized as holdings with unknown transaction codes, and the summary data show no reported buys, sells, exercises, gifts, or tax-withholding events.

Pharvaris (PHVS) CFO discloses common stock and option holdings

Q: How many Pharvaris (PHVS) common shares does the CFO directly hold?

The CFO directly holds 123,925 Pharvaris common shares . This total includes shares underlying restricted stock units that were previously granted and remain outstanding, which settle in common stock and vest according to specified schedules in the equity plan.

Q: What are the expiration dates of the Pharvaris (PHVS) CFO’s stock options?

The reported stock options expire on April 15, 2034 , August 1, 2034 , April 12, 2035 , and March 3, 2036 . Each option series has its own vesting schedule, often with 25% vested by a specific date and the rest vesting monthly.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Pharvaris N.V. filed an initial ownership report for its CFO / CLO, Nassif David W., detailing his current equity position in the company. He directly holds 123,925 shares of common stock and several stock option grants over Pharvaris shares.

These options cover 60,000 shares at $28.00 per share expiring in 2036, 60,000 shares at $16.05 expiring in 2035, 75,000 shares at $15.94 expiring in 2034, and 230,000 shares at $20.15 also expiring in 2034. The common share holdings include restricted stock units that vest over time, such as a 20,000-unit award granted in March 2026 with 25% vesting in March 2027 and the remainder vesting monthly.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Nassif David W.

Role CFO / CLO

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 60,000 shares (Direct); Common Stock — 123,925 shares (Direct)

Footnotes (1)

Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -20,000 RSUs from an award granted March 3, 2026 of which 25% will vest March 3, 2027 with the remainder vesting monthly thereafter; -15,000 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -14,198 RSUs from an award granted August 1, 2024 of which 25% vested August 1, 2025 with the remainder vesting monthly thereafter; -35,750 RSUs from an award granted April 15, 2024 of which 25% vested April 15, 2025 with the remainder vesting monthly thereafter; 25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on August 1, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on April 15, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.

Understanding Insider Trading Forms →

03/18/2026 - 02:23 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Nassif David W.

(Last)

(First)

(Middle)

1 CRANBERRY HILL SUITE 400

LEXINGTON

(Street)

LEXINGTON

MASSACHUSETTS

02421

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CFO / CLO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	123,925⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	03/03/2036	Common Stock	60,000	$28	D
Stock Option (Right to Buy)	⁽³⁾	04/12/2035	Common Stock	60,000	$16.05	D
Stock Option (Right to Buy)	⁽⁴⁾	08/01/2034	Common Stock	75,000	$15.94	D
Stock Option (Right to Buy)	⁽⁵⁾	04/15/2034	Common Stock	230,000	$20.15	D

Explanation of Responses:

1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -20,000 RSUs from an award granted March 3, 2026 of which 25% will vest March 3, 2027 with the remainder vesting monthly thereafter; -15,000 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -14,198 RSUs from an award granted August 1, 2024 of which 25% vested August 1, 2025 with the remainder vesting monthly thereafter; -35,750 RSUs from an award granted April 15, 2024 of which 25% vested April 15, 2025 with the remainder vesting monthly thereafter;

2. 25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter.

3. 25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.

4. 25% of the option vested on August 1, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.

5. 25% of the option vested on April 15, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for David Nassif	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the Pharvaris (PHVS) Form 3 filing for Nassif David W. show?

The Form 3 shows Pharvaris CFO / CLO Nassif David W.’s initial equity ownership. It lists 123,925 common shares plus multiple stock option grants and restricted stock units that vest over time under the company’s equity plan.

How many Pharvaris (PHVS) common shares does the CFO directly hold?

The CFO directly holds 123,925 Pharvaris common shares. This total includes shares underlying restricted stock units that were previously granted and remain outstanding, which settle in common stock and vest according to specified schedules in the equity plan.

What stock options in Pharvaris (PHVS) are reported for the CFO?

The filing reports stock options over Pharvaris common shares with exercise prices of $28.00, $16.05, $15.94, and $20.15. These options cover blocks of 60,000, 60,000, 75,000, and 230,000 underlying shares, expiring between 2034 and 2036.

How do the Pharvaris (PHVS) CFO’s restricted stock units vest?

The restricted stock units vest in tranches, typically with 25% vesting on the first anniversary and the balance vesting monthly. For example, a 20,000-unit award granted March 3, 2026 vests 25% on March 3, 2027, with remaining units vesting monthly thereafter.

What are the expiration dates of the Pharvaris (PHVS) CFO’s stock options?

The reported stock options expire on April 15, 2034, August 1, 2034, April 12, 2035, and March 3, 2036. Each option series has its own vesting schedule, often with 25% vested by a specific date and the rest vesting monthly.